Development of nanobiosensor for therapeutic drug monitoring in personalized cancer treatment approach
Cansu İlke Kuru Deniz Sipahi Ceren Aydoğan Fulden Ulucan-Karnak Sinan Akgöl a Buca Municipality Buca Science and Art Center,Izmir,Turkeyb Faculty of Science,Department of Biochemistry,Ege University,Izmir,Turkeyc Health Science Institute,Department of Medical Biochemistry,Ege University,Izmir,Turkeyd Nanotechnology Research and Application Center,Sabancı University,Istanbul,Turkey
DOI: https://doi.org/10.1080/09205063.2024.2356965
2024-06-12
Journal of Biomaterials Science Polymer Edition
Abstract:Docetaxel is one of the most effective and safe chemotherapy drugs according to the World Health Organization, but its clinical use has been discontinued due to its various side effects. To reduce these side effects, the amount of docetaxel drug should be kept at the most effective level, it should be monitored in body fluids. Due to the limitations of traditional analytical methods used for this purpose, such as expensive and low sensitivity, labor-intensive and time-consuming complex preliminary preparation, efficient methods are required for the determination of the docetaxel level in the body. The increasing demand for the development of personalized therapy has recently spurred significant research into biosensors for the detection of drugs and other chemical compounds. In this study, an electrochemical-based portable nanobiosensor system was developed for the rapid, low-cost, and sensitive determination of docetaxel. In this context, mg-p(HEMA)-IMEO nanoparticles to be used as nanobiosensor bioactive layer was synthesized, characterized, and docetaxel determination conditions were optimized. According to the results obtained, the developed nanobiosensor system can detect docetaxel with a sensitivity of 2.22 mg/mL in a wide calibration range of 0.25-10 mg/mL, in only 15 min, in mixed media such as commercially available artificial blood serum and urine. determined. We concluded that the developed nanobiosensor system can be successfully used in routine drug monitoring as a low-cost biomedical device capable of direct, rapid, and specific drug determination within the scope of personalized treatment, providing point-of-care testing. In the graphical abstract, the nanobiosensor system for the docetaxel anticancer drug developed within the scope of the study is schematized. Nanoparticles with developed magnetic properties and modified specifically for docetaxel are used as a bioactive layer on the surface of the disposable surface imprinted electrode, and blood or urine samples taken from patients provide the amount of docetaxel in their content with potentiostat measurements, through this bioactive layer.
engineering, biomedical,materials science, biomaterials,polymer science